Huntington's Disease Treatment Market Report by Type (Symptomatic Treatment, Disease-modifying Therapies), Drug Type (Approved Drugs, Off-label Drugs), Age (Below 50 Years, Above 50 Years), Distribution Channel (Drug Stores and Retail Pharmacies, Hospital

Huntington's Disease Treatment Market Report by Type (Symptomatic Treatment, Disease-modifying Therapies), Drug Type (Approved Drugs, Off-label Drugs), Age (Below 50 Years, Above 50 Years), Distribution Channel (Drug Stores and Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, and Others), and Region 2024-2032


The global Huntington's disease treatment market size reached US$ 491.1 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,248.1 Million by 2032, exhibiting a growth rate (CAGR) of 17.9% during 2024-2032. The rising incidences of Huntington’s disease, the increasing demand for advanced drugs for the disease treatment, and recent development of innovative therapeutic approaches represent some of the key factors driving the market.

Huntington's disease refers to a fatal neurodegenerative disorder that causes the progressive breakdown of nerve cells in the brain. Its symptoms include various movement, psychiatric, and cognitive impairments, such as involuntary jerking, muscle problems, difficulty in organizing and focusing, lack of awareness, insomnia, and social withdrawal. Huntington's disease treatment involves the application of various drugs, such as antipsychotics, antidepressants, antiparkinsonians, and mood-stabilizing drugs. The treatment process also includes various therapies, such as speech, occupational, physical, and psychotherapy. Huntington's disease treatment helps in minimizing the symptoms of movement and psychiatric disorders, assists patients in adapting to new abilities in a shorter time, and develops coping strategies. It also aids in improving everyday tasks, speech, maintaining posture and balance, and enhancing the quality of life.

Huntington's Disease Treatment Market Trends:
The rising incidence of Huntington's disease across the globe is one of the primary factors driving the market growth. Huntington's disease treatment is widely used to suppress involuntary jerking and writhing movement, treat chorea, reduce violent outbursts and agitation, and enhance strength, flexibility, balance, and coordination, which, in turn, improves the quality of life and enhances the patient's ability to carry out daily routine tasks, such as eating, communications, and walking. Furthermore, the increasing demand for advanced drugs to control the motor, cognitive, and psychiatric symptoms associated with Huntington's disease is providing an impetus to the market growth. In line with this, the rapid development of new disease-modifying drugs owing to the improved understanding of the disease, and its underlying causes are acting as another growth-inducing factor. Additionally, the recent development of the innovative therapeutic approach that deters the growth of Huntington's disease by reducing mutant huntingtin (mTT) production levels is positively influencing the market. Apart from this, the introduction of antisense technology that uses antisense oligonucleotides (ASOs) to target huntingtin (HTT) messenger ribonucleic acid (mRNA) and its protein throughout the central nervous system (CNS) is propelling the market growth. Moreover, increasing initiatives by several governments to promote the development of novel drugs are favoring the market growth. Other factors, including rising awareness among the masses regarding Huntington's disease, significant growth in the healthcare industry, increasing investment in research and development (R&D) activities, rising geriatric population, and escalating demand for off-label medications, are anticipated to drive the market growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global Huntington's disease treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, drug type, age, distribution channel, and end user.

Type Insights:

Symptomatic Treatment
Disease-modifying Therapies

The report has also provided a detailed breakup and analysis of the Huntington's disease treatment market based on the type. This includes symptomatic treatment and disease-modifying therapies. According to the report, symptomatic treatment represented the largest segment.

Drug Type Insights:

Approved Drugs
Tetrabenazine
Deutetrabenazine
Off-label Drugs

A detailed breakup and analysis of the Huntington's disease treatment market based on the drug type has been provided in the report. This includes approved drugs (tetrabenazine and deutetrabenazine) and off-label drugs. According to the report, approved drugs accounted for the largest market share.

Age Insights:

Below 50 Years
Above 50 Years

A detailed breakup and analysis of the Huntington's disease treatment market based on the age has been provided in the report. This includes below 50 years and above 50 years. According to the report, below 50 years accounted for the largest market share.

Distribution Channel Insights:

Drug Stores and Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

A detailed breakup and analysis of the Huntington's disease treatment market based on the distribution channel has been provided in the report. This includes drug store and retail, hospital, and online pharmacies. According to the report, drug store and retail pharmacies accounted for the largest market share.

End User Insights:

Hospitals
Homecare
Specialty Clinics
Others

A detailed breakup and analysis of the Huntington's disease treatment market based on the end users has been provided in the report. This includes hospitals, homecare, specialty clinics, and others.

Regional Insights:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for Huntington's disease treatment. Some of the factors driving the North America Huntington's disease treatment market includes significant technological advancements, the rapid development of healthcare infrastructure, and the rising number of individuals suffering from Huntington's disease.

Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global Huntington's disease treatment market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AOP Health, Apotex Inc., Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals PLC, Lupin Limited, Prilenia Therapeutics, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Vaccinex Inc. etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

1. What was the size of the global Huntington’s disease treatment market in 2023?
2. What is the expected growth rate of the global Huntington’s disease treatment market during 2024-2032?
3. What are the key factors driving the global Huntington’s disease treatment market?
4. What has been the impact of COVID-19 on the global Huntington’s disease treatment market?
5. What is the breakup of the global Huntington’s disease treatment market based on the type?
6. What is the breakup of the global Huntington’s disease treatment market based on the drug type?
7. What is the breakup of the global Huntington’s disease treatment market based on the age?
8. What is the breakup of the global Huntington’s disease treatment market based on the distribution channel?
9. What are the key regions in the global Huntington’s disease treatment market?
10. Who are the key players/companies in the global Huntington’s disease treatment market?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Huntington's Disease Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Symptomatic Treatment
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Disease-modifying Therapies
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Drug Type
7.1 Approved Drugs
7.1.1 Market Trends
7.1.2 Key Segments
7.1.2.1 Tetrabenazine
7.1.2.2 Deutetrabenazine
7.1.3 Market Forecast
7.2 Off-label Drugs
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Age
8.1 Below 50 Years
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Above 50 Years
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Distribution Channel
9.1 Drug Store and Retail Pharmacies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Hospital Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Online Pharmacies
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by End User
10.1 Hospitals
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Homecare
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Specialty Clinics
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Others
10.4.1 Market Trends
10.4.2 Market Forecast
11 Market Breakup by Region
11.1 North America
11.1.1 United States
11.1.1.1 Market Trends
11.1.1.2 Market Forecast
11.1.2 Canada
11.1.2.1 Market Trends
11.1.2.2 Market Forecast
11.2 Asia-Pacific
11.2.1 China
11.2.1.1 Market Trends
11.2.1.2 Market Forecast
11.2.2 Japan
11.2.2.1 Market Trends
11.2.2.2 Market Forecast
11.2.3 India
11.2.3.1 Market Trends
11.2.3.2 Market Forecast
11.2.4 South Korea
11.2.4.1 Market Trends
11.2.4.2 Market Forecast
11.2.5 Australia
11.2.5.1 Market Trends
11.2.5.2 Market Forecast
11.2.6 Indonesia
11.2.6.1 Market Trends
11.2.6.2 Market Forecast
11.2.7 Others
11.2.7.1 Market Trends
11.2.7.2 Market Forecast
11.3 Europe
11.3.1 Germany
11.3.1.1 Market Trends
11.3.1.2 Market Forecast
11.3.2 France
11.3.2.1 Market Trends
11.3.2.2 Market Forecast
11.3.3 United Kingdom
11.3.3.1 Market Trends
11.3.3.2 Market Forecast
11.3.4 Italy
11.3.4.1 Market Trends
11.3.4.2 Market Forecast
11.3.5 Spain
11.3.5.1 Market Trends
11.3.5.2 Market Forecast
11.3.6 Russia
11.3.6.1 Market Trends
11.3.6.2 Market Forecast
11.3.7 Others
11.3.7.1 Market Trends
11.3.7.2 Market Forecast
11.4 Latin America
11.4.1 Brazil
11.4.1.1 Market Trends
11.4.1.2 Market Forecast
11.4.2 Mexico
11.4.2.1 Market Trends
11.4.2.2 Market Forecast
11.4.3 Others
11.4.3.1 Market Trends
11.4.3.2 Market Forecast
11.5 Middle East and Africa
11.5.1 Market Trends
11.5.2 Market Breakup by Country
11.5.3 Market Forecast
12 Drivers, Restraints, and Opportunities
12.1 Overview
12.2 Drivers
12.3 Restraints
12.4 Opportunities
13 Value Chain Analysis
14 Porters Five Forces Analysis
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes
15 Price Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 AOP Health
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.2 Apotex Inc.
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.2.3 SWOT Analysis
16.3.3 Dr. Reddy’s Laboratories Ltd.
16.3.3.1 Company Overview
16.3.3.2 Product Portfolio
16.3.3.3 Financials
16.3.3.4 SWOT Analysis
16.3.4 H. Lundbeck A/S
16.3.4.1 Company Overview
16.3.4.2 Product Portfolio
16.3.4.3 Financials
16.3.4.4 SWOT Analysis
16.3.5 Hikma Pharmaceuticals PLC
16.3.5.1 Company Overview
16.3.5.2 Product Portfolio
16.3.5.3 Financials
16.3.5.4 SWOT Analysis
16.3.6 Lupin Limited
16.3.6.1 Company Overview
16.3.6.2 Product Portfolio
16.3.6.3 Financials
16.3.6.4 SWOT Analysis
16.3.7 Prilenia Therapeutics
16.3.7.1 Company Overview
16.3.7.2 Product Portfolio
16.3.8 Sun Pharmaceutical Industries Limited
16.3.8.1 Company Overview
16.3.8.2 Product Portfolio
16.3.8.3 Financials
16.3.8.4 SWOT Analysis
16.3.9 Teva Pharmaceutical Industries Ltd.
16.3.9.1 Company Overview
16.3.9.2 Product Portfolio
16.3.9.3 Financials
16.3.9.4 SWOT Analysis
16.3.10 Vaccinex Inc.
16.3.10.1 Company Overview
16.3.10.2 Product Portfolio
16.3.10.3 Financials
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings